Stevanato Group Reports Financial Results for the First Quarter of 2024

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2024. First Quarter 2024 Highlights Revenue for the first quarter of 2024 decreased 1% to €236.0 million compared with the same period last year, and high-value solutions represented 37% of total revenue.